|
WO2008121893A1
|
|
Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
|
|
WO2008121882A1
|
|
Improved methods of administration of adenosine a1 receptor antagonists
|
|
AU2007288312A1
|
|
KW-3902 conjugates that do not cross the blood-brain barrier
|
|
CN101506209A
|
|
Kw-3902 conjugates that do not cross the blood-brain barrier
|
|
EP2035009A1
|
|
Prolonged improvement of renal function comprising infrequent administration of an aa1ra
|
|
EP2035092A2
|
|
Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
|
|
CN101472583A
|
|
Method of improved diuresis in individuals with impaired renal function
|
|
CN101420958A
|
|
Throw altogether and adenosine A 1Receptor antagonist and anticonvulsant
|
|
AU2006240366A1
|
|
Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
|
|
WO2005105083A1
|
|
Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
|
|
EP1932529A1
|
|
Method of improved diuresis in individuals with impaired renal function
|
|
NZ543109A
|
|
Method of improved diuresis in individuals with impaired renal function
|
|
AU2004216133A1
|
|
Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases
|
|
CN1753661A
|
|
Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
|
